6/6 Taiwan Life Sciences Biweekly Newsletter
2022-06-06 |
| Taiwan Life Sciences Biweekly |
| 1. Biomedical AI firm Medimaging Integrated Solution shows strong first day as publicly listed company 2 June, 2022 Taiwan's first biomedical AI company Medimaging Integrated Solution (TW: 6796) was listed on the local stock market June 1st and enjoyed a strong first day. The company has performed well in recent years, last year booking an EPS over NT$2.3. On its first day of listing, Medimaging stock price rose 16.95 percent to close at NT$53.8. Medimaging's consolidated revenue last year was NT$486 million with after-tax net profit at NT$66 million. Revenue and profit grew 20.89 percent and 22.22 percent respectively. More... (in Chinese) |
| 2. Center Laboratories pushes for new CDMO business opportunities 1 June, 2022 To grab a slice of global biopharmaceutical CDMO (Contract Development and Manufacturing Organization) business, Center Laboratories (TW: 4123) announced last week that it will participate in a capital increase of new shares to be issued by the group's subsidiary TOT Biopharm (HK: 1875) at a maximum of HKD 110 million. This will complement existing resources such as its investment in CDMO firm Mycenax Biotech Inc. (TW: 4726) to create geographical synergies, according to the company. Lin Rongjin, chairman of Center Laboratories, said that with the growing size of the group the company intends to increase investment in its existing bio-related investments, including in Mycenax, Lumosa Therapeutics, Biogend Therapeutics, Medeon Biodesign, and others. The group is aiming to build seven to eight biotech unicorns by 2025, and aims to also increase its liquid assets from NT$40 billion this year to NT$100 billion by 2025. More... (in Chinese) |
| 3. Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization 31 May, 2022 Foresee Pharmaceuticals (6576.TWO), announced today that the European Commission (EC) has approved the Marketing Authorization Application (MAA) for CAMCEVI® 42 mg prolonged-release suspension for injection, for the treatment of hormone-dependent advanced prostate cancer and for the treatment of high-risk localized prostate cancer and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. The approval is applicable to all 27 European Union (EU) Member States, Iceland, Norway and Liechtenstein. More... |
| 4. To upgrade its CDMO capacity, Bora Biologics invests NT$1.68 billion in Hsinchu Science Park 31 May, 2022 Taiwan's Ministry of Science and Technology announced today that it had approved 10 investment projects with a total value of NT$3.4231 billion. Among them, Bora Biologics Co., Ltd. which will invest NT$1.68 billion yuan into facilities in Hsinchu Science Park. This investment by Bora Biologics is expected to expand its biopharmaceutical CDMO (Contract Development and Manufacturing Organization) capacity. Bora Biologics' main products are monoclonal antibody biosimilar drugs. More... (in Chinese) |
| 5. PharmaEssentia's new blood cancer drug to enter Japan and Latin America markets 29 May, 2022 PharmaEssentia (TW: 6446) recently held a shareholders' meeting to report on the progress of overseas market development of its new rare blood cancer drug Ropeginterferon alfa-2b (Ropeg). CEO Ko-Chung Lin said that the company expects to obtain drug approval for Japan in the first half of next year. PharmaEssentia also announced last week that its Board of Directors approved the authorization of PharmaEssentia to expand into the Latin American market. More... (in Chinese) |
| 6. PharmaTher fleshes out ketamine delivery portfolio with deal for on-body injector 27 May, 2022 The ketamine drug delivery deals keep coming. PharmaTher is again involved in the latest agreement, teaming up with [Taiwan's] CC Biotechnology Corporation (CCBIO) to access a wearable delivery device that should be ready for the clinic early next year. More... |
 |
| 7. TTY Biopharm news: Clinical development of Octreotide LAR microsphere begins, first batch of cancer drug Arsenic Trioxide shipped to the US 27 May, 2022 TTY Biopharm (TW: 4105) announced on May 26 that its drug Octreotide LAR microsphere injection dosage form, developed with an international partner last year, will officially enter clinical development. TTY Biopharm will receive from its partner a milestone payment of US$500,000, according to the company. In addition, the company reported that its first self-developed and US-certified drug Arsenic Trioxide for the treatment of acute promyelocytic leukemia was successfully shipped at the end of March and is already being sold in the United States. More... (in Chinese) |
| 8. Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutralizing efficacy 26 May, 2022 Taiwanese biotech outfit AcadeMab has broken new ground in the development of COVID immunotherapies through the development of a potentially life-saving monoclonal antibodies for COVID-19 patients using single B cell technology, shows the best neutralization ability (IC50 = 11.4 and 4.3 ng/ml) in both Omicron variants BA.1 and BA.2 respectively. More... |
| 9. ABVC BioPharma Engaged by [Taiwan's] Orion BioTech to Identify Global Licensing Partners 25 May, 2022 ABVC Biopharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has been engaged by Orion BioTech, Inc., a medical device company based in Taipei, Taiwan, to identify candidates interested in out-licensing Orion developmental products, such as Orion’s “Lamina Cover” for spine surgery, its “Wireless Intracranial Pressure (ICP) Monitor” for brain surgery and its “Auto-stop Drill” for orthopedic surgery. The Lamina Cover recently received U.S. F.D.A. medical device 510(k) approval. More... |
| 10. Qisda forms gene tech partnership 23 May, 2022 Electronics maker Qisda Corp and TCI Co, which manufactures health food, functional beverages and skincare products, on Friday said that they would form a strategic alliance through a private placement. Under the deal, Qisda plans to acquire 4.72 million shares in a TCI subsidiary, TCI Gene Inc, at NT$115.5 per share, the company’s regulatory filing showed on Friday. More... |
| ============================== Taiwan Bio Industry Organization | TEL: 886-27836028 | Email: biotaiwan@gmail.com |